Investigator Studies Program (MISP): Diabetes and Metabolism
Effective October 2020, the Diabetes & Metabolism Investigator Studies Program (MISP) Committee will accept proposals within our current areas of interest (AOI) up to May 13, 2021 for the second review cycle. This is a competitive process; decisions will be made on the basis of scientific merit and strategic fit within the AOI. The program requests that investigators specify how they will support diversity in enrollment to include traditionally underrepresented minorities/ethnic groups.
The following areas are of interest to the Investigator Studies Program Committee:
- Clinical and mechanistic studies regarding the effects of SGLT2 inhibition on renal function in patients with and without T2DM
- Clinical and mechanistic studies regarding the effects of SGLT2 inhibition on the cardio-renal axis in patients with and without T2DM
- Effects of SGLT2 inhibition and GLP-1 RA in combination on metabolic regulators, substrate metabolism, volume status, renal and cardiac function, and CV outcomes
Please complete a Protocol and detailed budget via Visiontracker
, the Company's on-line study management system (in US). The proposals will be collectively reviewed and selected by the Diabetes and Metabolism MISP Committee.
This site is intended for US investigators only. Investigators outside of the US interested in submitting research proposals to the Investigator
Studies Program should contact their local MSD office